Фармакоэкономическая оценка влияния терапии Нолипрелом на бремя артериальной гипертонии

Леонова Марина Васильевна, Чурилин Юрий Юрьевич, Чапурин Сергей Анатольевич et al. · HYPERTENSION · 2010

The paper addresses evaluation of economic burden of arterial hypertension in real practice in Russia based on epidemiologic and pharmacoepidemiologic studies and the results of OPTIMAX study. Markov model in 10-year time horizon perspective was used to estimate efficacy of fixed combination of Perindorpil and Indapamide (Noliprel, Servier, France) in hypertensive patients. 3 age female and male groups (under 50, 55 and 60 years old) were formed; direct (personal expenses, expenses of public health budget) and indirect costs (loss of salary, collection of taxes, social expenses) were estimated. Treatment with Noliprel is more effective considering life expectancy and prevention of complications in hypertensive patients as compared to usual treatment AH. Antihypertensive therapy used in real practice demonstrates relatively low direct costs, but high indirect costs; with aging direct costs increase and demands in medical assistance and indirect costs decrease. Noliprel use has cost-saving effect, in particular in men under 50 and 55 years old by decreasing economic burden. Despite the growth of personal expenses (Noliprel cost), public health care budget is saved by the decrease of medical assistance demand in all hypertensive groups (about 2,4-10,4 thousand rubles per patient). Cost of 1 QALY (quality-adjusted life year) shows cost-saving effect of Noliprel treatment in male groups under 50 and 55 years old; in other groups additional expenses are under 2 thousand rubles.

Cited by 0 works.

Authors